See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.
Treatment Development and Delivery Program
eagle-i ID
http://eagle-i.itmat.upenn.edu/i/0000016e-6529-1d3c-cb39-247480000000
Resource Type
Properties
-
-
Resource Description
-
Program Goals
Despite the fact that cigarette smoking continues to be the greatest preventable cause of morbidity and mortality, there are currently only three FDA-approved medications for nicotine dependence: nicotine replacement therapy (NRT; transdermal nicotine (TN), nasal spray, gum, lozenge), bupropion, and varenicline. Although these treatments are effective for some smokers, nearly 75% relapse within a year. There is a clear need to identify novel treatment approaches to help more smokers quit.
The Treatment Development and Delivery Program within CIRNA is guided by the following goals: (1) to develop and evaluate novel behavioral and pharmacological interventions for nicotine dependence; (2) to develop novel methods to improve the efficacy and effectiveness of FDA-approved treatment for nicotine dependence; (3) to expand the use of treatments for nicotine dependence to under-served populations.
-
-
Contact
-
Schnoll, Robert., PhD
-
-
Affiliation
-
Center for Interdisciplinary Research on Nicotine Addiction
-
-
Website(s)
-
https://www.med.upenn.edu/cirna/treatment-development-and-delivery.html
-
-
Other members
-
Lerman, Caryn., PhD
-
-
Other members
-
Audrain-McGovern, Janet., PhD
